vendredi 24 mars 2017

Onco Actu du 24 mars 2017


1. Biologie

Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug [Mass. General Hospital]

2.5 Etiologie - Gènes

DNA typos to blame for most cancer mutations [Nature]

Most cancer mutations arise from ‘bad luck,’ but many cases still preventable, researchers say [STAT]

New Study Finds That Most Cancer Mutations are Due to Random DNA Copying ‘Mistakes’ [Johns Hopkins]

Cancer Is Partly Caused By Bad Luck, Study Finds [NPR]

Two thirds of cancers are unavoidable even if you live a healthy life, study finds [The Telegraph]

More than two-thirds of cancer mutations are due to random DNA copying errors, study says [Washington Post]

‘Bad luck’ with random DNA errors is responsible for two-thirds of cancer mutations, study says [LA Times]

Debate reignites over the contributions of ‘bad luck’ mutations to cancer [Science]

Is cancer just a matter of random bad luck? [CNN]

Two thirds of cancers caused by random genetic mistakes: U.S. study [Reuters]

4.10 Dép., diag. & prono. - Poumon

Health coalition forms National Lung Cancer Roundtable to increase screening and reduce lung cancer deaths [ACS]

4.12 Biopsies liquides

Blood test detects cancer and pinpoints location...before symptoms appear [The Telegraph]

5. Traitements

Giving pancreatic cancer patients better opportunities to join clinical trials [Cancer Research UK]

New era in precision medicine for pancreatic cancer [Cancer Research UK]

Major pancreatic cancer study launched [BBC News]

5.10 Traitements - Essais

NIH achieves milestone to accelerate multisite clinical studies [NIH]

5.2.2 Pharma - Fusions & Acquisitions

BioLineRx buys Agalimmune to expand cancer pipeline [FierceBiotech]

Tessa buys Euchloe for suite of checkpoint inhibitors [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Bidding war for European Medicines Agency intensifies as Article 50 trigger looms [Science Business]

Use of big data to improve human and animal health [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio [FierceBiotech]

Pfizer, Merck KGaA score a landmark FDA OK for checkpoint contender avelumab [EndPoints]

FDA approves first treatment for rare form of skin cancer [FDA]

FDA approves Pfizer, German Merck immunotherapy for skin cancer [Reuters]

5.9 AACR

Bayer to Showcase Data on Growing Oncology Pipeline at AACR 2017 [Bayer]

6.1 Observation

Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson [NCI]

6.6 Publications

The findings of medical research are disseminated too slowly [The Economist]

Gates Foundation announces open-access publishing venture [Nature]